As radiopharmaceutical therapy (RPT) expands beyond neuroendocrine tumors and prostate cancer, it is important to understand ...
The necessity for standardization in clinical PET/CT protocols was acknowledged and initiated nearly 20 y ago (1–4). This recognition mainly stemmed from multicenter trials focused on quantifying and ...
Journal of Nuclear Medicine June 2026, jnumed.126.272389; DOI: https://doi.org/10.2967/jnumed.126.272389 Radiopharmaceutical therapy (RPT) has emerged as a radiation ...
In vivo pretargeting stands as a promising approach to harnessing the exquisite tumor-targeting properties of antibodies for nuclear imaging and therapy while simultaneously skirting their ...
The introduction of total-body PET, or long–axial-field-of-view (LAFOV) PET, has led to high-quality imaging by improving sensitivity through its increased axial coverage and volume of detector ...
Journal of Nuclear Medicine April 2026, jnumed.126.272204; DOI: https://doi.org/10.2967/jnumed.126.272204 ...
Journal of Nuclear Medicine June 2026, jnumed.126.272009; DOI: https://doi.org/10.2967/jnumed.126.272009 ...
The U.S. Food and Drug Administration and the European Medicines Agency approved the first prostate-specific membrane antigen (PSMA)–targeted radiopharmaceutical therapy (RPT), 177Lu-PSMA-617 ...
Actinomycosis is a rare gram-positive infection, generally granulomatous. The diagnosis can be complex and sometimes can be achieved only at the chronic stage. Actinomyces normally colonize the mouth, ...
Bone metastases are common, especially in more prevalent malignancies such as breast and prostate cancer. They cause significant morbidity and draw on health-care resources. Molecular and hybrid ...
Overall Survival with [177 Lu]Lu-PSMA-617 Versus [177 Lu]Lu-PSMA I&T: A Propensity Score–Matched Real-World Analysis ...
This review outlines the technical aspects and diagnostic performance parameters of nuclear medicine procedures used on patients with disorders of the lower gastrointestinal tract, with the exclusion ...